Gilead Places Restrictions on 340B Drug Pricing for Hepatitis C Treatments
Sydney Otomancek2022-05-19T20:17:09-04:00May 19th, 2022|Categories: Featured, Industry News|Tags: drugpricing, HEOR, HepC, pharma|
The drugmaker Gilead cut off 340B discounts for certain hepatitis C drugs to some hospitals if they do not provide [...]
Receive essential insights, resources and content direct to your inbox!
Hit subscribe to stay informed!
Advertisement
Latest News
Featured Webinars
Practical AI: Adding Insight to the Patient Journey with Digital Phenotyping
Thursday, May 23, 2024
Sponsor: OM1
Insights from the 2024 Salary Survey Report by HealthEconomics.com
Wednesday, May 1, 2024
Webinar Host: Scientist.com
Beyond Accelerated Approvals: External Control Arms
Wednesday, April 10, 2024
Sponsor: Cardinal Health
Categories
Artificial Intelligence
Careers
Clinical Trials
Cost Effectiveness
Data Analytics & Syndicated Reports
Healthcare Financing
Health Databases
Health Equity
Health Policy
Health Tech Assessment
HEOR
Integrated Evidence Assessment & Planning
Market Access
Medical Affairs
Patient Outcomes & Engagement
Press Release
Pricing & Reimbursement
Real World Data
Real World Evidence
Value Assessment
Value Communication